Biogen acquires three new drugs

Share this article:
Embattled Tysabri maker Biogen Idec announced an agreement yesterday with biopharmaceutical company Protein Design Labs to purchase a multiple sclerosis drug and two other experimental products for approximately $800 million.
As part of the deal, Biogen will initially pay Protein Design $40 million and purchase $100 million of stock from the Fremont, Calif. company.
The agreement covers Protein Design's experimental multiple sclerosis drug daclizumab, which is in Phase II trials. Biogen will also gain rights to a cancer treatment called volociximab, being tested in patients with skin, kidney and pancreatic cancers, and a third drug, Huzaf, being studied in the treatment of Crohn's disease.
Biogen Idec is continuing with a review of its own multiple sclerosis drug Tysabri. The drug was voluntarily removed from the market in March after being linked to deaths from progressive multifocal leukoencephalopathy, a rare neurological disease most often found in patients with compromised immune systems.
Biogen Idec and Elan told MM&M earlier this year it expects to issue a decision on Tysabri in the second half of 2005.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.